Akeso Reports P-Ib/II Trial Data on Cadonilimab Combination to Treat NSCLC

Why It Matters

The data suggest cadonilimab‑based combos could fill a therapeutic gap for PD‑(L)1‑resistant NSCLC, offering longer disease control and a biomarker‑driven strategy that may reshape second‑line treatment standards.

Key Takeaways

• 6‑month PFS rate reached 55.7% overall.
• Median PFS 7 months across all patients.
• Disease control rate hit 95.2% in trial.
• Objective response rate 26.2% with combo therapy.
• ctDNA clearance correlated with 9.1‑month median PFS.

Pulse Analysis

Non‑small cell lung cancer remains the leading cause of cancer mortality, and a growing subset of patients now face progression after frontline PD‑(L)1 inhibitor therapy. Immuno‑oncology developers have turned to bispecific antibodies to broaden checkpoint inhibition, and cadonilimab—targeting both PD‑1 and CTLA‑4—offers a mechanistic rationale for overcoming adaptive resistance. By pairing cadonilimab with the anti‑angiogenic agent anlotinib and the chemotherapeutic docetaxel, Akeso aims to synergize immune activation, vascular normalization, and cytotoxic kill, a strategy increasingly favored in refractory disease settings.

The Phase Ib/II trial reported a 55.7% six‑month PFS rate and a median PFS of seven months, outcomes that compare favorably with historical second‑line benchmarks for PD‑(L)1‑refractory NSCLC. Disease control was exceptionally high at 95.2%, and an objective response rate of 26.2% was observed despite the heavily pre‑treated cohort. Subgroup analysis revealed consistent benefits in squamous histology and in tumors expressing PD‑L1 ≥1%, indicating the regimen’s broad applicability. Moreover, ctDNA clearance after one cycle correlated with a median PFS of 9.1 months, positioning liquid biopsy as a real‑time predictor of therapeutic success.

If validated in larger Phase III studies, this combination could challenge existing standards such as docetaxel alone or newer immuno‑combo regimens, potentially earning a niche in guideline‑recommended options for PD‑(L)1‑resistant NSCLC. The biomarker insight also opens avenues for adaptive trial designs, where ctDNA dynamics guide treatment continuation or escalation. Investors and clinicians alike will watch Akeso’s upcoming regulatory filings, as the data hint at a differentiated product that blends immunotherapy, targeted angiogenesis, and chemotherapy into a single, potentially practice‑changing package.